Advanced search
Publication Cover
Scandinavian Journal of Clinical and Laboratory Investigation Volume 61, 2001 - Issue 6
Submit an article Journal homepage
27
Views
12
CrossRef citations to date
0
Altmetric
Research Article

Serum levels of parathyroid hormone and markers of bone metabolism in patients with rheumatoid arthritis. Relationship to disease activity and glucocorticoid treatment

T Jensen Department of Rheumatology,
,
M Hansen Department of Rheumatology,
,
J. C. Madsen Department of Clinical Chemistry
,
G Kollerup Department of Endocrinology, H:S Hvidovre Hospital, University of Copenhagen, Copenhagen, Denmark;
,
M Stoltenberg Department of Rheumatology,
,
A Florescu Osteoporosis Research Center, Copenhagen Municipal Hospital;
&
P Schwarz Department of Rheumatology, Rigshospitalet,University of Copenhagen,Copenhagen,Denmark
 show all
Pages 491-501 | Published online: 08 Jul 2009

  • Deodhar AA, Woolf AD. Bone mass measurement and bone metabolism in RA: a review. Br J Rheumatol 1996; 35: 309-22.
  • Gough AKS, Lilley J, Eyre S, Holder RL, Emery P. Generalised bone loss in patients with early rheumatoid arthritis. Lancet 1994; 344: 23-7.
  • Hansen M, Florescu A, Stoltenberg M, Pødenphant J, Zbinden-Petersen B, Hørslev-Petersen K, Hyldstrup L, Lorenzen I. Bone loss in rheumatoid arthritis. Scand J Rheumatol 1996; 25: 367-76.
  • Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis. Rheum Dis Clin North Am 1994; 20: 629-50.
  • Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89: 309-19.
  • Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93: 165-76.
  • Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis. Nature 1999; 397: 315-23.
  • Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin. Nature 1999; 402:304-9.
  • Gravallese EM, Manning C, Tsay A, Naito A, Pan C, Amento E, Goldring SR. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum. 2000; 43: 250-8.
  • Hansen M, Pødenphant J, Florescu A, Stoltenberg M, Borch A, Kluger E, Sørensen SF, Hansen TM. A randomised trial of differentiated prednisolone therapy in active rheumatoid arthritis. Clinical benefits and skeletal effects. Ann Rheum Dis 1999; 58:713-18.
  • Hofbauer LC, Gori F, Riggs LB, Lacey DL, Dunstan CR, Spelsberg TC, Khosla S. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 1999; 140:4382-9.
  • Manolagas SC, Jilka RL. Bone marrow, cytokines and bone remodelling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 1995:332:305-31.
  • Morris HA, Need AG, O'Loughlin PD, Horowitz M, Bridges A, Nordin BEC. Malabsorption of calcium in corticosteroid-induced osteoporosis. Calcif Tissue Int 1990; 46: 305-8.
  • Suzuki Y, Ichikawa Y, Saito E, Homma M. Importance of increased urinary calcium excretion in the development of secondary hyperparathyroidism of patients under glucocorticoid therapy. Metabolism 1983; 2: 151-6.
  • Hattersley AT, Meeran K, Burrin J, Hill P, Shiner R, Ibbertson HK. The effect of long- and short-term corticosteroids on plasma calcitonin and parathyroid hormone levels. Calcif Tissue Int 1994; 54: 198-202.
  • Paz-Pacheco E, Fuhleihan GEH, LeBoff MS. Intact parathyroid hormone levels are not elevated in glucocorticoid-treated subjects. J Bone Miner Res 1995; 10: 1713-18.
  • Al-Awadhi A, Olusi S, Al-Zaid N, Prabha K. Serum concentrations of interleukin6,osteocalcin, intact parathyroid hormone, and markers of bone resorption in patients with rheumatoid arthritis. J Rheumatol 1999; 26: 1250-6.
  • Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
  • Schwarz P, Sørensen HA, McNair P, Transbøl I. Cica-clamp technique: a method for quantifying parathyroid hormone secretion: a sequential citrate and calcium clamp study. Eur J Clin Invest 1993;23:546-53.
  • Kollerup G, Thamsborg G, Bhatia H, Sørensen OH. Quantitation of urinary hydroxypyridinium cross-links from collagen by high-performance liquid chromatography. Scand J Clin Lab Invest 1992; 52: 657-62.
  • Cosman F, Nieves J, Herbert J, Shen V, Lindsay R. High-dose glucocorticoids in multiple sclerosis patients exert direct effects on the kidney and skeleton. J Bone Miner Res 1994; 9: 1097-104.
  • Morony S, Capparelli C, Lee R, Shimamoto G, Boone T, Lacey DL, Dunstan CR. A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1 ß, TNF-a, PTH, PTHrP, and 1,25(OH)2D3. J Bone Miner Res 1999; 14: 1478-85.
  • Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996; 14: 397-440.
  • Funk JL, Cordaro LA, Wei H, Benjamin JB, Yocum DE. Synovium as a source of increased amino-terminal parathyroid hormone-related protein expression in rheumatoid arthritis. J Clin Invest 1998; 101: 1362-71.
  • Gevers G, Devos P, De Roo M, Dequeker J. Increased levels of osteocalcin (serum bone glaprotein) in rheumatoid arthritis. Br J Rheum 1986; 25: 260-2.
  • Kröger H, Risteli J, Risteli L, Penttilä I, Alhava E. Serum osteocalcin and carboxyterminal propeptide of type I procollagen in rheumatoid arthritis. Ann Rheum Dis 1993; 52: 338-42.
  • Lems WF, Gerrits MI, Jacobs JWG, van Vugt RM, van Rijn HJM, Bijlsma JWJ. Changes in (markers of) bone metabolism during high dose corticosteroid pulse treatment in patients with rheumatoid arthritis. Ann Rheum Dis 1996; 55: 288-93.
  • Hall GM, Specter TD, Delmas PD. Markers of bone metabolism in postmenopausal women with rheumatoid arthritis. Arthritis Rheum 1995; 38: 902-6.
  • Ellies LG, Aubin JE. Temporal sequence of interleukin 1a-mediated stimulation and inhibition of bone formation by isolated fetal rat calvaria cells in vitro. Cytokine 1990; 2:430-7.
  • Ebeling PR, Peterson JM, Riggs BL. Utility of type I procollagen propeptide assays for assessing abnormalities in metabolic bone diseases. J Bone Miner Res 1992; 7: 1243-50.
  • Sharif M, Salisbury C, Taylor DJ, Kirwan JR. Changes in biochemical markers of joint tissue metabolism in a randomized controlled trial of glucocorticoid in early rheumatoid arthritis. Arthritis Rheum 1998; 41: 1203-9.
  • Quarles LD. Prednisone-induced osteopenia in beagles: variable effects mediated by differential suppression of bone formation. Am J Physiol 1992; 263: E136-41.
  • Delany AM, Gabbitas BY, Canalis E. Cortisol downregulates osteoblasts a-1 (I) procollagen mRNA by transcriptional and post-transcriptional mechanisms. J Cell Biochem 1995; 57: 488-94.
  • Kotowicz MA, Hall S, Hunder GG, Cedel SL, Mann KG, Riggs BL. Relationship of glucocorticoid dosage to serum bone gla-protein concentration in patients with rheumatologic disorders. Arthritis Rheum 1990; 33: 1487-92.
  • Harris ED. Rheumatoid arthritis. Pathopysiology and implications for therapy. N Engl J Med 1990; 322: 1277-89.
  • Seibel MJ, Robins SP, Bilezikian JP. Urinary pyridinium crosslinks of collagen. Specific markers of bone resorption in metabolic bone disease. Trends Endocrinol Metab 1992; 3: 263-70.
  • Seibel MJ, Duncan A, Robins SP. Urinary hydroxy-pyridinium crosslinks provide indices of cartilage and bone involvement in arthritic diseases. J Rheumatol 1989; 16: 964-70.
  • Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994; 79: 1693-700.
  • Gough AKS, Peel NFA, Eastell R, Holder RL, Lilley J, Emery P. Excretion of pyridinium crosslinks correlates with disease activity and appendicular bone loss in early rheumatoid arthritis. Ann Rheum Dis 1994; 53: 14-17.
  • Sinigaglia L, Varenna M, Binelli L, Bartucci F, Arrigoni M, Ferrara R, Abbiati G. Urinary and synovial pyridinium crosslink concentrations in patients with rheumatoid arthritis and osteoarthritis. Ann Rheum Dis 1995; 54: 144-7.
  • Guanabens N, Pares A, Alvarez L, Martinez De Osaba MJ, Monegal A, Peris P, et al. Collagenrelated markers of bone turnover reflect the severity of liver fibrosis in patients with primary biliary cirrhosis. J Bone Miner Res 1998; 13: 731-8.
  • Mø11er S, Hansen M, Hillingsø J, Jensen J-EB, Henriksen JH. Elevated carboxy terminal cross-linked telopeptide of type I collagen in alcoholic cirrhosis: relation to liver and kidney function and bone metabolism. Gut 1999; 44: 417-23.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.